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Aim: The aim of this study was to compare the effectiveness of two radiotherapy schedules
in  patients with bone metastases.
Background: We  analyzed the need for re-irradiation, rates of pain control, pathological
fractures, and functionality in patients randomized to single-fraction (8 Gy 1×) or multiple-
fraction radiotherapy (3 Gy 10×)  with at least 12 months follow-up, during ﬁve years. The
hypothesis was that the two radiotherapy schedules are equally effective.
Materials and methods: Ninety patients with painful skeletal metastases were randomized to
receive single fraction (8 Gy) or multiple fraction (3 Gy 10×)  radiotherapy.
Results: In the single-fraction group, seven pathological fractures occurred (15.5%) versus
two  (4.4%) in the multiple-fraction group. There was no statistically signiﬁcant difference
between the time it took to suffer a pathological fracture in both groups (p = 0.099). Patients
in  the single-fraction group received twelve re-irradiations (26.6%), four in the multiple-
fraction group (8.8%), with no signiﬁcant difference between time elapsed before the ﬁrst
re-irradiation (p = 0.438).
Conclusion: This study shows no difference between the two groups for the majority of
patients with painful bone metastases. Patients were followed up during ﬁve years, and
the  trial showed no disadvantage for 8 Gy 1× compared to 3 Gy 10×.  Despite the fact that
the  pathological fracture rate is 3.75 times higher in the single-fraction group, this sched-ule  is considered more convenient for patients and more cost-effective for radiotherapy
departments.
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1.  Background
Bone metastases are a common manifestation of distant
relapse for many  types of solid cancer, especially those arising
in the lung, breast and prostate. This condition is associ-
ated with signiﬁcant and debilitating pain, compression of
the spinal cord, reduced physical function and pathological
fractures.
Almost 80% of patients with solid tumors will develop
painful bone metastases to the spine, pelvis and extremi-
ties during the course of their illness.1 The goals of palliative
treatment of bone metastases are pain relief, preservation of
function, and maintenance of skeletal integrity. When bone
pain is limited to a single or a limited number of sites, local
ﬁeld external beam radiation therapy (EBRT) to the painful
sites can provide pain relief in 80–90% of cases,2,3 with com-
plete pain response obtained in 50–60%.3–5
There is strong evidence that pain relief lasts for at least
6 months in at least 50% of the patients.2 Although treat-
ment can be effective for patients with mild, moderate and
severe pain, early interventions may be useful in maintain-
ing the quality of life and minimizing side effects of analgesic
medications.6 In addition to relieving pain, radiotherapy may
prevent pathological fractures, maintain activity and mobility,
and, rarely, prolong survival. Although almost all the patients
eventually die of their disease, some survive for several years.
So, ﬁnding the optimal palliative treatment both with a short
and long-term perspective is crucial.
Several systematic reviews and randomized studies have
compared 8 Gy single-fraction radiotherapy with a multi-
fraction schedule. These two regimens are now considered
equivalent regarding pain control and the need for anal-
gesics is similar whether a single or multiple fractions are
received, without signiﬁcant difference in the incidence of
spinal cord compression.7–9 On the other hand, some reports
indicate that patients receiving a single-fraction experience
more  pathological fractures and are more  likely to be treated
with re-irradiation to the same site compared to patients
receiving multiple fractions.7–11 Some authors argued that for
patients with a relatively long live expectancy, a fractionated
regimen may be considered.7
2.  Aim
The aim of this study was a global assessment of the results
in the control of pain, duration of response and retreatment
rate comparing patients who received a single-fraction radio-
therapy (8 Gy 1×) and a multiple-fraction therapy (3 Gy 10×)
in a prospective-randomized study with ﬁve years of follow-
up. Secondary objectives were: assessment of the functional
response of the patient; evaluation of the rate of recalciﬁcation
and evaluation of the incidence of pathologic fractures.
3.  Materials  and  methodsWe  performed a prospective randomized study of 98 patients
diagnosed with metastatic disease to the bone level, treated
in the Radiation Oncology Department in Puerta del Mariotherapy 1 9 ( 2 0 1 4 ) 405–411
Universitary Hospital in Cádiz, Spain, who  were treated
between January 2005 and December 2006. Follow-up had
been discontinued for four patients because of aggravated
conditions and another four patients were excluded because
of incomplete records. Thus, a total of 90 patients with
painful bone metastases were included in the present analysis
(Table 1).
Considered for inclusion in this study were valid patients
with histologically proven malignant primary tumor (biopsy,
cytology) or radiological conﬁrmation of metastatic bone
lesion (veriﬁed either by bone X-ray, bone scan, computer
tomography (CT) or magnetic resonance imaging (MRI)). There
were no restrictions regarding the site of bone metastases.
We excluded patients with Karnofsky Performance below 50%,
those who had large bony lesions on the spine or pelvis that
required orthopedic surgery (before or after a pathological
fracture) and those who manifested spinal cord compres-
sion, patients with poor prognosis with life expectancy less
than 6 weeks. We  did not include patients that had previ-
ously undergone radiotherapy to the actual symptom site, and
those unable to complete the quality of life assessment tools.
The study pre-treatment of patients included in this study
was to conduct a thorough history and physical examination
usually with blood count and biochemistry. Assessment of
pain was done according to visual analogue scale (VAS) (0–10
with 0: absent pain, and 10: maximum pain imaginable).12
We assessed the state of functionality, such as degree of
impairment of mobility and quality of life,13 according to the
following scale based on Barthel index of activities of daily liv-
ing: 1 – normal use without pain (100 total independence (90
being high if the patient uses a wheelchair)); 2 – normal use
with pain (60 small dependence); 3 – use is signiﬁcantly limited
(35–55 moderate dependence); 4 – no functionality (<35 severe
dependence). Also, we  made an assessment of the analgesia-
requirements. Clinical and radiological ﬁndings determined
the target volume. If the patient had more  than one index
site, all targets were treated at the same time. In the case
of lesions in the long bones or pelvis, we took a 4 cm mar-
gin of apparently normal bone, or above the articular surface,
encompassing the wide-spread bone lesion, and lesions of
the spine; patients were treated with a single ﬁeld, with cal-
culation of dose to the depth of 6 cm,  involving the affected
vertebra and two vertebrae above and below, following the pro-
tocol of the RTOG 74-02. The radiation therapy was delivered
using a linear accelerator with 6 or 15 MV photon energy, with
three-dimensional conformal techniques. 45 patients (50%)
received a traditional scheme of 30 Gy in 10 fractions 3 Gy per
fraction, 5 fractions per week. The remaining patients (50%)
received a single-fraction radiotherapy (8 Gy 1×). Patients were
evaluated weekly during treatment for acute toxicity, need
of analgesic treatment or modiﬁcation of other concurrent
medications, in addition to the response to treatment. After
radiation treatment, the following assessments were made:
pain, following the VAS, and the response to pain (complete:
without pain, good: two or more  levels down the pain, poor or
slight: only decreases the pain level, null: remains unchanged);
state of functionality: the degree of disruption and, follow-
ing the same scale as in the initial study prior to treatment;
requirements for analgesia (measuring the response as: com-
plete: no pain without analgesia, good or partial: precise
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Table 1 – Baseline characteristics of the patients.
8 Gy 1× 3 Gy 10× Total p
Number of patients 45 (50%) 45 (50%) 90 (100%)
Age mean 62.6 61.8 62.2
Gender 0.830
Male 28 (62.2%) 26 (57.7%) 54 (60%)
Female 17 (37.8%) 19 (42.3%) 36 (40%)
Karnofsky performance 74.2% 72.4% 73.3% 0.136
Diagnosis
Lung cancer 5  (11.1%) 9 (20%) 14 (15.6%) 0.9
Prostate cancer 14 (31.1%) 17 (37.8%) 31 (34.4%) 0.178
Breast cancer 18 (40%) 9 (20%) 27 (30%) 0.870
Other types of cancer 8 (17.8%) 10 (22.2%) 18 (20%) 0.9
Differentiated grade 1/2/3 3/29/13 1/33/11 4/62/24 0.635
Primary treatment site
Limbs 7 (15.6%) 3 (6.7%) 10 (11.1%)
Axial skeletal bones 28 (62.2%) 33 (73.3%) 61 (67.8%)
Limbs + axial bones 6 (13.3%) 3 (6.7%) 9 (10%)
Cranial bones 3 (6.7%) 1 (2.2%) 4 (4.4%)
Axial + cranial bones 0 1 (2.2%) 1 (1.1%)
Limbs + cranial bones 1 (2.2%) 4 (8.9%) 5 (5.6%)
Number metastases 0.662
Single/multiple 15 (33.4%)/30 (66.6%) 18 (40%)/27 (60%) 33 (36.7%)/57 (63.3%)
Soft tissue mass associated
Yes/No 27 (60%)/18 (40%) 26 (57.8%)/19 (42.3%) 37 (41.2%)/53 (58.8%) 1.0
Visceral metastases
Yes/No 8 (17.8%)/37 (82.2%) 12 (26.7%)/33 (73.3%) 20 (22.2%)/70 (77.8%) 0.447
Pretreatment pain (1–10) 7.84 95%CI 7.44–8.24 7.76 95%CI 7.35–8.16 7.8 0.753
Time pretreatment pain (month) 2.84 95%CI 2.34–3.34 2.99 95%CI 2.33–3.65 2.92 m 0.892
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eFunction pretreatment
Grade 1/2/3/4%patient) 0/28.8/62.3/8.9 
ype anti-inﬂammatory medication, poor or slight: required
nalgesics morphine type, null: no relief despite medication).
onitoring of patients was also performed at 15, 30, 60, 90
ays of treatment completion, 6 months to a year, perform-
ng the same evaluations as that at the end of radiotherapy
reatment.
Patients who  died during the study or failed to follow, did
ot attend the review, were assessed until they remained
n the study. Data were collected by the authors from
he patients’ records; we  registered the following parame-
ers during ﬁve years: data of inclusion, date of death or
ate of last record if alive, irradiation regimen received,
natomical treatment site, pathological fractures (fracture in
reviously irradiated area conﬁrmed by X-ray), pain, function,
e-calciﬁcation (in lytic bone metastases studied by X-ray 3,
 and 12 months post-treatment) and re-irradiation (irradia-
ion administered to the same anatomical site, if more  than
ne such re-irradiation had been given, the ﬁrst one was the
ne registered, to allow comparison in time to the ﬁrst re-
rradiation).
The frequencies of endpoints were compared between
he two  groups using the chi-square test (2). Two-sided
-values <0.05 were considered signiﬁcant. Baseline character-
stics between groups were tested by chi-square and binomial
ests. The overall survival in the groups was estimated using
aplan–Meyer analyses and signiﬁcant difference was eval-
ated using Log-Rank test, like actuarial analysis of time to
e-irradiation by tumor site. Mann–Whitney U-test was used
o estimate the difference between the two arms in the time
lapsed before the ﬁrst re-irradiation. The statistical software2.2/20/62.3/15.5 1.1/24.4/62.2/12.2 0.546
SPSS for Windows version 13.0 was employed. The study was
done in accordance with the Helsinki Declaration.
4.  Results
A total of 90 patients were included in the study, 60% men
(n = 54) and 40% women (n = 36). Baseline characteristics of
patients in the two groups are shown in Table 1. There were
no major differences between the two arms. The most preva-
lent diagnoses were cancer of the prostate (34.4%), breast (30%)
and lung (15.6%). Histological grade were moderately differen-
tiated in 62 patients and poorly in 24; only 4 patients were well
differentiated.
The most common primary treatment sites were the
axial skeletal bones (pelvis and column) n = 61. 57 patients
(63.3%) had multiple bone metastases, and 20 (22.2%) had syn-
chronous visceral metastases. There were soft tissue masses
associated in 37 patients. Mean intensity of pretreatment pain
using VAS was 7.8 regardless of gender and age and mean time
pretreatment pain was 2.92 months. We found no signiﬁcant
differences in analgesia applied to patients in both groups, in
each of the reviews. The following values of signiﬁcance (p-
value) were obtained: First follow-up (f-u): 0.673, second f-u:
0.816, third f-u: 0.281, fourth f-u: 0.480, ﬁfth f-u: 0.083, and
sixth f-u: 0.560.There was no difference between the two  groups in total
reduction of analgesic treatment (p = 0.934) (Fig. 1). Karnof-
sky Performance (p = 0.011) and recalciﬁcation (p = 0.007) were
inﬂuenced signiﬁcantly. Less signiﬁcant was the inﬂuence on
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Fig. 1 – Survival functions and total reduction of analgesic
treatment.
Breast cancer patients (median survival: 12.4 months) had sig-
niﬁcantly longer survival than lung cancer (p = 0.000) with 2.3functionality (p = 0.038) and initial size of the bone metastases
(p = 0.089), if soft tissue was affected (p = 0.078) and if there is
more  than one bone metastasis (p = 0.093).
There was no difference when we analyzed time to reduce
one analgesic’s level (p = 0.781) between the two treatments
groups.
Response study to review and review between the ﬁrst
and last reviews there were no signiﬁcant differences in pain
response, relative to declining levels of analgesia, between the
ﬁrst and last reviews or between successive reviews: reduc-
tion of analgesia between visits 1 and 2 (p = 0.736), between
visits 2 and 3 (p = 0.715), between 3 and 4 follow up (p = 1.0),
between visits 4 and 5 (p = 0.317), between 5 and 6 follow-
up (p = 1.0) and reduction of analgesia between visits 1 and
6 (p = 0.794). A complete response at 4 weeks was observed in
17% and partial response in 62% (overall response (OR) rate
of 79%) of patients in the 8-Gy arm, and in patients in the
30-Gy arm, the complete response (CR) and partial response
(PR) rates were 18% and 70%, respectively (OR rate 88%). At 3
months CR, PR and OR were 13%, 53%, and 66% for 8 Gy, and
15%, 59%, and 74% for 30 Gy. No signiﬁcant differences were
observed between the two arms. In patients who achieved
response (OR), the mean of response duration was 26 weeks
for the 30-Gy schedule and 23 weeks for the 8-Gy schedule.
These differences are not statistically signiﬁcant and the same
resulted in patients who achieved a CR with a mean response
of 29 and 26 weeks for the 30-Gy and the 8-Gy schedules,
respectively.
We evaluated functionality pretreatment according to the
functionality scale: 1: one patient; 2: 22 patients, 3: 56 patients,
and 4 (no functionality): 11 patients. There was no difference
in time to improve a grade of functionality between the two
treatment groups (p = 0.339). In the single-fraction group, half
of the patients experienced improvement with this treatment
at least 2 months after the treatment ended (CI (1.1–2.9), with
a mean of 4.8 months (CI (3.3–6.4). In the multiple-fraction
group, the median value is 2 months (CI (1.3–2.7), and the mean
is 5.4 months (CI (3.9–6.9).iotherapy 1 9 ( 2 0 1 4 ) 405–411
No differences were found in time to obtain normal use
without pain (Barthel index 1 (p = 0.549)). In the single-fraction
group, the mean value was 7 months (CI: 5–9), and the median
was of 6 m.  In the multiple-fraction group, the mean value was
5, (CI: 4–7), and the median was of 2 m,  and the inﬂuenced vari-
ables were recalciﬁcation (p = 0.000), soft tissue mass present
(p = 0.037) and pathological fracture (p = 0.094). Study of the
response with respect to obtaining reduction of at least one
level in functionality, revision to revision showed: follow-up 1
and 2. p: 0.281, 2 and 3 follow-up p: 0.383, follow-up 3 and 4 p:
0.674, follow-up 4 and 5 p: 1.000.
No signiﬁcant differences were found between the two
groups in recalciﬁcation. The ratio of difference between
recalciﬁcation rates was 0.881. None of the variables studied
appears to affect decisively the rate of recalciﬁcation.
In the single-fraction group, seven pathological fractures
occurred (15.5%) versus two (4.4%) in the multiple-fraction
group. Pathological fracture rate is 3.75 times higher for
individuals with single fractionation than for those receiv-
ing multiple-fraction treatments. There was no statistically
signiﬁcant difference between the time it takes to suffer
pathological fracture in both groups (p = 0.099) (see Table 2).
Patients in the single-fraction group received six re-
irradiations (13.3%) compared to four in the multiple-fraction
group (8.8%), and most of them (65%) were given within the
ﬁrst 8 months (see Table 2). However, there was no signif-
icant difference between the time elapsed before the ﬁrst
re-irradiation between the two groups (p = 0.438). The most
affected variables or those that best describe the retreat time
are total reduction in analgesia (p = 0.0209), Karnofsky perfor-
mance status (p = 0.088), and the fact of reducing in at least
one level of analgesia (p = 0.047).
Actuarial analysis to compare the two treatment arms
according to metastatic bone site and the presence of skeletal-
related events was performed, but the numbers were too small
for a valid statistical comparison. Of re-irradiations, 5 (50%)
were delivered to the spinal column, 3 (30%) to pelvic bones,
and 2 (20%) to lower limbs. There were a total of 9 patho-
logical fractures, ﬁve (55.5%) in the pelvis, 3(33.3%) in the
lower limbs, and one (11.1%) in the upper limbs. In relation
to the type of cancer, rate of re-irradiation and time-interval
to re-irradiation, actuarial analysis was performed, but all the
numbers were too small for a valid statistical comparison
between the two schedules.
The estimated median survival, and follow-up time accord-
ing to treatment was 7.9 months in the hypo-fractionated
group (8 Gy) and 8.73 months in the multi-fractionated group
(30 Gy), and no statistically signiﬁcant difference in overall sur-
vival was demonstrated (p = 0.495). Despite the fact that death
rate for the single-fraction is 1.23 times higher than for the
multi-fraction treatment (Fig. 2).
The variables that best describe overall survival are: pri-
mary  cancer diagnosis (p = 0.000), Karnofsky performance
status (p = 0.001), presence of visceral metastases (p = 0.000),
and histological differentiated grade (p = 0.034). There were
major differences according to primary cancer diagnosis.months median survival and prostate cancer (p = 0.048) with
8.6 months median survival.
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Table 2 – Pathological fractures and re-irradiations according to primary treatment regimen (n = 90).
8 Gy 30 Gy p-value Total
Pathological fracture 7 (15.5%a) 2 (4.4%) 0.099 9 (10%b)
Re-irradiation 6 (13.3%) 4 (8.8%) 0.043 12 (13.3%)
Skeletal-related eventsc 13 (28.8%) 6 (13.3%) 21 (23.3%)
Total 45 (100%) 45 (100%) 90 (100%)
a Percent within treatment arms.
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c Includes at least one event of re-irradiation or pathological fracture
.  Discussion
he high incidence of cancer patients, as well as greater con-
rol rates, lead to a higher proportion of patients with painful
one metastases to radiation treatment. Bone metastases can
ause severe and debilitating effects, including pain, spinal
ord compression, hypercalcemia, and pathologic fracture.
BRT provides successful palliation of painful bone metas-
ases that is time efﬁcient and has been associated with very
ew side effects.12–14 External beam radiotherapy can provide
igniﬁcant palliation of painful bone metastases in 50–80%
atients, with up to one-third of patients achieving complete
ain relief at the treated site.15 Widespread variation exists
n worldwide practice patterns for palliative radiation dose
ractionation schedules.16
Multiple prospective randomized trials have shown pain
elief equivalence for dosing schema, including 30 Gy in 10
ractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions, and a single Gy fraction for patients with previously unirradiated painful
one metastases.6,8,10–13,18 Several meta-analyses9,15,19
ave compared different radiotherapy schedules and have
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ig. 2 – Survival functions and overall survival in 90
atients treated with single or multiple-fraction
adiotherapy.wing irradiation for bone metastases.
concluded that single-fraction radiotherapy is as effective as
multifraction radiotherapy in terms of pain relief. However,
for neuropathic pain, Roos et al.20 compared 8 Gy vs. 20 Gy
and concluded that a single fraction was not so effective as
multifractionated and they recommended 20 Gy for those
patients. Fractionated radiotherapy courses have been associ-
ated with an 8% repeat treatment rate to the same anatomic
site because of recurrent pain vs. 20% after a single fraction;
however, the single fraction treatment approach optimizes
patient and caregiver convenience.6,15 In addition it is more
cost-effective for radiotherapy departments.7,9,17–19,21–22
The mean of response duration was 26 weeks for the
30 Gy schedule and 23 weeks for the 8 Gy schedule, this dif-
ference is not statistically signiﬁcant. The results are similar
to those in other series published, which range from 11 to
24 weeks. In the study by Niewald,13 response duration was
the same for both treatment arms, whereas Gaze et al.23
reports a 13.5 week response duration for the single frac-
tion course vs. 14 weeks for the multifraction course in his
series. In the study of van der Linden et al.,17 the duration
of response was 18 weeks for a single fraction and 19 weeks
for a multifraction with no signiﬁcant differences between the
schemes.
Patients in the single-fraction group receive signiﬁcantly
more  re-irradiations (13.3%) as compared to patients receiv-
ing multiple-fractions (8.8%). Consequently, there was also a
signiﬁcant difference in skeletal-related events. This differ-
ence is signiﬁcant, as in the case of the study of Hartsell
et al.11 where 18% of the patients in the 8 Gy arm received re-
irradiation vs. 9% in the 30 Gy arm (p < 0.001). These results are
observed in almost all reported randomized trials. Steenland
et al.7 observed 25% re-treatments in the 8 Gy group and 7%
in the 24 Gy group and conﬁrmed by Chow’s metaanalysis15
that shows that in single dose treatments reirradiation is
2.5 times higher than in protracted schedules. The percent-
age of re-irradiation ranges from 11% to 42% according to
the literature.7,9,15,19 The meta-analyses carried out by Wu
et al.19 and Sze et al.9 also show a higher incidence of re-
irradiation for the single fraction arm compared with the
multifraction arm. Speciﬁcally, Sze’s meta-analysis9 shows
that in patients receiving the single-fraction course, the inci-
dence of re-irradiation was 21.5% compared with 7.4% in the
multifraction arm. It has been suggested that it reﬂects prior
uncertainty concerning the long-term effect of single-fraction
therapy.10 Another possibility is that pain response following
8 Gy is less durable, resulting in more  frequent re-irradiation,
but some studies have concluded that this is unlikely.7,24 Sev-
eral authors have suggested that this reﬂects a tendency of
many  oncologists to have a lower threshold for re-irradiation
d rad
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after single-fraction treatment compared to multiple-fraction
schedule.7–11,18
There were no signiﬁcant differences between the time
elapsed before the ﬁrst re-irradiation between the two groups
(p = 0.438). This indicates that duration of pain relief was simi-
lar for the two regimens, as conﬁrmed by other studies.7,10,22,24
Single-fraction does not make it more  likely for clinicians to
admit the patients earlier for re-irradiation, so an oncologist
does not have a lower threshold for re-irradiation after 8 Gy
than after multiple-fraction therapy. The most affected vari-
ables or those that best describe the retreat time are: total
reduction in analgesia (p = 0.0209), Karnofsky performance sta-
tus (p = 0.088), and the fact of reducing in at least one level
of analgesia (p = 0.047). Radiotherapy was repeated for symp-
tomatic relapse in patients who were initially responders.
There were no signiﬁcant differences between the time it
took to suffer pathological fracture in both groups (p = 0.099),
but pathological fracture rate was 3.75 times higher for indi-
viduals with single fractionation than for those receiving
multiple-fraction treatments. The only included endpoints
were those in the same anatomical site as the index lesion.
Other studies have reported similar results7,9–11; however
other authors show no difference with long term follow-
up.20,24 In assessing which factors inﬂuence the rate of
pathologic fracture, the only one showing a signiﬁcant value
is the variable type of fractionation.
We  analyzed intensity of pretreatment pain using the
VAS (mean: 7.8) and time pretreatment pain (mean: 2.92
month). Like other studies, there was no difference between
the two groups in total reduction of analgesic treatment
(p = 0.934).2,3,10,11,20,22,25 The inﬂuenced variables were Karnof-
sky Performance (p = 0.011) and recalciﬁcation (p = 0.007).
There was no difference when we analyzed time to reduce one
level of analgesics (p = 0.781) between the two groups. Other
variables, such as functionality (p = 0.038), soft tissue involve-
ment (p = 0.078), initial size of the metastatic bone lesion
(p = 0.089), and multiple metastatic bone lesion (p = 0.093) were
affected to a lesser degree. Secondly, we  analyzed the response
to pain reduction relative to some level of analgesia, without
signiﬁcant differences between the two groups. In our work,
by analyzing the response in reducing pain at some level of
analgesia, given in response to an improvement in pain by
one level, there were no statistically signiﬁcant differences
between the two groups studied, (p = 0.938), with a ratio of the
functions of 1.019.
We  evaluated functionality pretreatment according to the
functionality scale: 1: one patient; 2: 22 patients; 3: 56 patients;
and 4: 11 patients. There was no difference in time to improve
a grade of functionality between the two groups (p = 0.339). No
differences were found in time to restore normal use with-
out pain (p = 0.549), these results are similar to those reported
by other trials,17,19,20,21,24,25 and the inﬂuenced variables were
recalciﬁcation (p = 0.000), soft tissue mass present (p = 0.037)
and pathological fracture (p = 0.094).
It is important to note that the survival period after pal-
liative radiotherapy usually was not related to the response
of the metastases, but to the progression of other tumor pro-
cess coexisting factors, altering the quality of life. At the study
of survival between the two groups, it appears that the sur-
vival between 5 and 8 months is slightly higher in the dailyiotherapy 1 9 ( 2 0 1 4 ) 405–411
fractionation scheme. Generally, the survival in 50% of
patients is at least 12 months. In the single-fraction group this
value is 11.67 months, which is slightly lower. The median sur-
vival time was 7.90, and 50% of patients survived more  than
8 months. In the multiple-fraction treatment schedule, the
mean survival time was 8.73 months; 50% of cases reached 11
months of life. Like Sande et al.,24 in our study, no statistically
signiﬁcant difference in overall survival was demonstrated
(p = 0.495) similar to results by other authors.25 Despite the fact
that death rate for the single-fraction was 1.23 times higher
than for the multi-fraction treatment.
By analyzing which factors inﬂuenced survival, we found
the following: location of the primary tumor, higher for
breast, worse for lung (p = 0.000), presence of other non-
bone metastatic location (p = 0.000); and performance status
(p = 0.001).
6.  Conclusions
This study presents that radiotherapy with a single-fraction
(8 Gy) and multi-fraction schedule (30 Gy) should be consid-
ered as equally efﬁcient for the majority of patients with
painful uncomplicated bone metastases. They were followed
up during ﬁve years, without difference for 8 Gy compared to
30 Gy. Therefore, we  recommended single-fraction therapy for
two reasons: greater convenience for the patients and more
cost-effective for radiotherapy departments.
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